Long Acting Neuraxial Peri-prostatic Block in Cancer
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Disease progression after definitive therapy for prostate cancer is a major source of morbidity and mortality. Adrenergic/sympathetic innervation of the prostate is essential for prostate cancer progression, and abrogation of these signals by blocking adrenergic innervation halts disease progression. Long-acting neuraxial block of the sympathetic nerves that innervate the pelvis with dehydrated alcohol (>98% Ethanol) is a safe and effective tool in the treatment of chronic pelvic pain and cancer- induced pelvic pain. Furthermore, ultrasound guided periprostatic neuraxial block at the time of prostate biopsy with short-acting lidocaine is standard of care. Herein the research team proposes to administer a long-acting periprostatic neuraxial block with dehydrated alcohol and lidocaine under trans rectal ultrasound guidance in patients with high-risk clinical features for prostate cancer at the time of prostate biopsy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- PSA >10
- PSAD >0.15
- PI-RADS 5 lesion on MRI
- Karnofsky performance status >80
- Ability to understand and the willingness to sign a written informed consent.
Exclusion criteria
- Prior or concomitant treatment for prostate cancer, including radiation therapy, focal therapy, cryo therapy, androgen deprivation therapy.
- Imaging or clinical evidence of metastatic disease.
- PSA > 100ng/mL
Trial design
Primary purpose
Allocation
Interventional model
Masking
12 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal